LC
AXSM icon

Lindbrook Capital’s Axsome Therapeutics AXSM Stock Holding History

Lindbrook Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$5.6M Sell
48,041
-14,103
-23% -$1.61M 0.52% 29
2024
Q4 		$5.26M Sell
62,144
-2,563
-4% -$236K 0.47% 33
2024
Q3 		$5.82M Sell
64,707
-5,619
-8% -$490K 0.52% 32
2024
Q2 		$5.66M Sell
70,326
-13,442
-16% -$995K 0.53% 31
2024
Q1 		$6.68M Sell
83,768
-318
-0.4% -$26.7K 0.63% 31
2023
Q4 		$6.69M Sell
84,086
-233
-0.3% -$15.6K 0.67% 25
2023
Q3 		$5.89M Sell
84,319
-150
-0.2% -$11.2K 0.66% 27
2023
Q2 		$6.07M Buy
84,469
+248
+0.3% +$18.3K 0.65% 25
2023
Q1 		$5.19M Sell
84,221
-329
-0.4% -$21.6K 0.61% 26
2022
Q4 		$6.52M Buy
84,550
+84,498
+162,496% +$5.05M 0.8% 18
2022
Q3 		$2K Buy
52
+43
+478% +$2.15K ﹤0.01% 1990
2022
Q2 		$0 Sell
9
-134
-94% -$4.24K ﹤0.01% 2486
2022
Q1 		$6K Sell
143
-7
-5% -$217 ﹤0.01% 1496
2021
Q4 		$6K Sell
150
-250
-63% -$9.2K ﹤0.01% 1430
2021
Q3 		$13K Sell
400
-500
-56% -$19.5K ﹤0.01% 892
2021
Q2 		$61K Hold
900
– – 0.01% 408
2021
Q1 		$51K Hold
900
– – 0.01% 434
2020
Q4 		$73K Buy
900
+200
+29% +$15K 0.02% 304
2020
Q3 		$50K Buy
+700
New +$54.5K 0.01% 358
2020
Q2 		– Sell
-76
Closed -$4K – 1720
2020
Q1 		$4K Sell
76
-324
-81% -$26.4K ﹤0.01% 1061
2019
Q4 		$41K Buy
+400
New +$16.2K 0.01% 500
2019
Q3 		– Sell
-400
Closed -$10K – 1437
2019
Q2 		$10K Buy
+400
New +$8.02K ﹤0.01% 887

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Lindbrook Capital's AXSM Position: Q1 2025 in Review

Lindbrook Capital reduced its Axsome Therapeutics (AXSM) stake by 23% in Q1 2025, selling an estimated $1.61M and leaving 48,041 shares worth $5.6M. The position accounts for 0.52% of the portfolio, ranked #29.

Lindbrook Capital first reported a position in AXSM in Q2 2019 and has held it in 22 quarters since. The position peaked at $6.69M in Q4 2023. 352 funds tracked by Wall St. Rank hold AXSM as of Q1 2025.

  • Lindbrook Capital held 48,041 shares of Axsome Therapeutics worth $5.6M as of Q1 2025.
  • Lindbrook Capital sold 14,103 Axsome Therapeutics shares in Q1 2025, an estimated $1.61M.
  • Axsome Therapeutics made up 0.52% of Lindbrook Capital's portfolio in Q1 2025, its #29 holding.
  • Lindbrook Capital first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 22 quarters since.
  • Lindbrook Capital's Axsome Therapeutics position peaked at $6.69M in Q4 2023.
  • 352 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.